One Genetic Test.
A Lifetime of Health Insights.
One sample
Two initial reports:
- Proactive Health Report
- Pharmacogenomics Report
Independent physician review
One-on-one genetic counseling
FSA/HSA eligible
Order Now
Make more informed health decisions throughout life with MyOme Personal Genome™. One sample provides insights into disease and medication response risk informed by your entire genome.
MyOme Personal Genome™
DISEASE PREVENTION
EARLY DETECTION
MEDICATION MANAGEMENT
Clinically relevant. Whole genome.
We provide a more complete picture of your disease risk through clinical-grade whole genome sequencing (30x coverage) and analysis–10 times more information than other tests–including rare and common variants and structural alterations.
Genetic information for every stage of your life.
Your genetic testing needs change over time. The MyOme Personal Genome™ platform enables you to receive on-demand health insights at every stage – from family planning to disease-risk information.
Dynamic technology. Actionable findings.
MyOme Personal Genome™ keeps up with the advances and understanding of biology. Our platform utilizes cutting-edge technologies, including machine learning and AI, so you can take advantage of new clinical research findings as they happen.
MyOme Personal Genome™ Reports
A single sample on the MyOme Personal Genome™ platform unlocks a lifetime of health insights.
This report identifies potential mutations in 81 genes known to result in conditions such as cancers, heart disease, metabolic conditions and others. These are deemed actionable findings by the American College of Medical Genetics and Genomics (ACMG).
This report summarizes known variants in 15 genes associated with response to medications that may be used by an independent healthcare provider to optimize your care.
Available Soon: Integrated Personal Risk Score Reports Combining Clinical Factors and Genetics Across Multiple Ancestries
Example of a Coronary Artery Disease (CAD) Integrated Personal Risk Score Report
Heart Health Test that Considers All of You
This report provides a single risk score that integrates genetics with clinical factors to assess risk for coronary artery disease (CAD), for those those who may be missed by clinical evaluation (whereas traditional genetic panels evaluate rare genes impacting a small percent and without assessing CAD risk).
MyOme Personal Genome™ members will be automatically notified.
Individualized Breast Cancer Testing for Life
If you have a family history of breast cancer but are negative for single-gene tests, including BRCA1 or BRCA2, you can still be at an elevated risk for breast cancer2. This report provides an integrated risk score that combines genetics with clinical risk factors for women without a known mutation in a breast cancer gene. This test is validated across multiple ancestries3.
MyOme Personal Genome™ members will be automatically notified.
Ordering Your MyOme Personal Genome™ Test
1
Enroll in the MyOme Platform
Submit your order via our secure online portal. A healthcare provider will review and if determined appropriate for you, will order your test.
2
Send Us Your Sample
Provide your sample right from home in the sample collection kit.
3
Receive Your Results
Access your first reports in the online portal. Genetic counseling is available.
4
Stay Updated
Access new reports for a low cost as they are added to the platform to stay informed on advances in clinical research.
Why MyOme Personal Genome™?
Committed to Data Privacy
At MyOme, your data is yours. You can request your DNA data anytime, and we never sell or share your data without your permission. In addition, our platform is HIPAA-compliant and features enterprise-scale data encryption.
Genetic Counselors Available
MyOme Personal Genome™ provides complimentary access to genetic counseling to help you understand your results and identify the next steps for your health.
Get More from MyOme Personal Genome™
| MyOme Personal Genome | Other Genetic Screening Tests4 | |
|---|---|---|
| Whole-genome Based Approach | 98% Yes, we sequence over 3,000,000,000 bases | ~0.2% No, they examine or sequence less than 900,000 bases |
| New Reports | Our whole-genome approach allows for lifelong genetic analyses as research evolves | No, their data is incomplete |
| Clinically Relevant | Yes, our reports focus on clinical risk where there's clear actionability | Limited clinical utility with a focus on other areas, such as ancestry |
| Re-interpreted Data | Yes, because we sequence your genome, your reports can be updated with the latest scientific findings | No, their data is limited to what they initially examined |
| Physician Ready | Yes, we provide a clinical report signed by a certified laboratory director ready to act on | Limitations of how they analyze your genome mean additional testing will likely be required |
| Privacy | We will never sell your data without your consent and we abide by industry-leading security protocols | Lack of transparency into how they might use your data |
| Genetic Counseling | Post-report genetic counseling is included through our partners | Not always available and often at an additional charge |
Frequently Asked Questions
Logistical
Pharmacogenomics
Clinical
Reports and Genetic Counseling
Costs
Stay Updated
Stay informed about the MyOme Personal Genome™ platform.
- 1.
- Rare Diseases Act of 2002. https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf
- 2.
- Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26: 1291–1299. doi:10.1093/annonc/mdv022
- 3.
- Tshiaba PT, Ratman DK, Sun JM, Tunstall TS, Levy B, Shah PS, et al. Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precis Oncol. 2023;7: e2200447. doi:10.1200/PO.22.00447
- 4.
- Saey, Tina Hesman. “What Genetic Tests like 23andMe Actually Told Me about My Health.” Science News, 21 Aug. 2019, https://www.sciencenews.org/article/review-genetic-tests-23andme-veritas-genos-health-comparison
- *
- In some cases an additional sample might be required.